LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings
 

About: LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.

Employees: 10

Healthcare Biotechnology
Price charts implemented using Lightweight Charts™